Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 2 2Phase 4 1Phase 1/2 1

Status

Recruiting 2Active not recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 5NIH 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 6Other 2Tumor-Agnostic 1Other hematologic neoplasm 1Breast 1

Conditions

Endometrial Neoplasms 5Overweight 2Obesity 2Endometrial Hyperplasia 2Neoplasms 1Infertility 1FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1

Interventions

Paclitaxel 74pembrolizumab 59Carboplatin 55Bevacizumab 54Specimen Handling 47Magnetic Resonance Spectroscopy 38Cisplatin 32olaparib 28Gemcitabine 25liposomal doxorubicin 24Biopsy 20Taxes 18Topotecan 17Nivolumab 17Doxorubicin 15Cyclophosphamide 15Immunoglobulin G 14Disulfides 14niraparib 12fludarabine 12lenvatinib 11Surveys and Questionnaires 11Letrozole 11atezolizumab 10Drug Therapy 10durvalumab 9Fulvestrant 9Docetaxel 9Brachytherapy 9mirvetuximab soravtansine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Megestrol Acetate × Gynecologic × 90 days × Clear all
NCT05247268 2026-06-04

Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer

Fudan University

Phase 2 Recruiting
104 enrolled
Gynecologic

Endometrial Neoplasms

NCT05316467 2026-06-04

Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma

Fudan University

Phase 2/3 Terminated
8 enrolled
GynecologicOther

Infertility, Obesity, Endometrial Neoplasms, Overweight

NCT03671811 2026-06-03

Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy

City of Hope Medical Center

Phase 2 Active not recruiting
44 enrolled 12 charts
Gynecologic

Endometrial Hyperplasia, Endometrial Neoplasms

NCT05255653 2026-05-15

RAINBO

Leiden University Medical Center

Phase 2/3 Recruiting
1,615 enrolled
Gynecologic

Endometrial Neoplasms

NCT05538897 2026-05-13

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled
Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

NCT07462663 2026-05-13

SHAPE-ENDO

Hospital Universitari de Bellvitge

Phase 4 Not yet recruiting
82 enrolled
GynecologicOther

Endometrial Hyperplasia, Neoplasms, Obesity, Endometrial Neoplasms, Overweight

Data powered by HemOnc (CC BY 4.0) Colophon âš¡